Rationale Neuroactive derivatives of steroid hormones, neurosteroids, can act on GABA A receptors (GABA A Rs) to potentiate the effects of GABA on these receptors. Neurosteroids become elevated to physiologically relevant levels under conditions characterized by increased steroid hormones. There is considerable evidence for plasticity of GABA A Rs associated with altered levels of neurosteroids which may counteract the fluctuations in the levels of these allosteric modulators. Objectives The objective of this review is to summarize the current literature on GABA A R plasticity under conditions characterized by alterations in neurosteroid levels, such as over the estrous cycle, during puberty, and throughout pregnancy and the postpartum period. Results The expression of specific GABA A R subunits is altered over the estrous cycle, at puberty, and throughout pregnancy and the postpartum period. Inability to regulate δ subunit-containing GABA A Rs throughout pregnancy and the postpartum period is associated with depression-like behavior restricted to the postpartum period. Conclusions GABA A R plasticity associated with alterations in neurosteroid levels represents a homeostatic compensatory mechanism to maintain an ideal level of inhibition to offset the potentiating effects of neurosteroids on GABAergic inhibition. Failure to properly regulate GABA A Rs under conditions of altered neurosteroid levels may increase vulnerability to mood disorders, such as premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and postpartum depression.
are associated with affective disorders, whilst highlighting the areas of therapeutic promise.
Neurosteroidogenesis
Neurosteroids are synthesized de novo in the brain from cholesterol (for a review, see Do Rego et al. 2009 ). However, due to their lipophilic nature, progesterone and other peripherally derived steroid hormones readily cross the blood-brain barrier where they can be locally metabolized to neurosteroids. Once in the brain, progesterone can be metabolized to allopregananolone by the consecutive enzymatic actions of 5α-reductase and 3α hydroxysteroid dehydrogenase (3α-HSD). The conversion of progesterone to allopregnanolone in the brain requires the availability of the necessary steroidogenic enzymes which are not universally expressed in all cell types or brain regions. In the mouse, 5α-reductase and 3α-HSD mRNA have both been detected in principal neuronal populations in the hippocampus, cortex, amygdala, thalamus, cerebellum and striatum suggesting that these are also neurosteroidogenic sites (Agis-Balboa et al. 2006) , whereas only limited expression was found in interneuron populations (Agis-Balboa et al. 2006) . Although it appears that neurosteroids are synthesized in principal neurons, it is unclear whether neurosteroids act on neurons in a paracrine or autocrine fashion (for a review, see Lambert et al. 2009 ).
In addition to the local metabolism of progesterone in the brain, allopregnanolone is also synthesized in the periphery where, once it enters the brain, it can influence neuronal excitability. In fertile women, allopregnanolone is synthesized in the corpus luteum peaking in the luteal phase with serum levels reaching up to 4 nmol/l compared to <1 nmol/l in the follicular phase (Andreen et al. 2009; Bicikova et al. 1998; Genazzani et al. 1998; Monteleone et al. 2000; Purdy et al. 1990; Wang et al. 1996) . Experimental evidence confirms the expression of the necessary steroidogenic enzymes 5α-reductase (Haning et al. 1996; Ottander et al. 2005 ) and 3α-HSD mRNA in human ovarian tissue (Ottander et al. 2005) , supporting its role in the cyclic changes in neurosteroid levels. Interestingly, allopregnanolone is still detected in the brain in ovariectomized rats , further demonstrating that local de novo neurosteroid synthesis also occurs in the brain. During pregnancy, however, the majority of allopregnanolone is synthesized in the placenta. Serum allopregnanolone measurements range from 40 to >100 nM in both rats ) and humans (Gilbert Evans et al. 2005; Hill et al. 2007; Luisi et al. 2000; Paul and Purdy 1992; Pearson Murphy et al. 2001 ) during pregnancy, which rapidly drop upon parturition. Levels in the brain may be even higher due to local neurosteroid synthesis, diffusion barriers and differences in metabolism (Mackenzie and Maguire 2013) . In addition, the potential for neurosteroids to accumulate in the membrane will not only increase their local concentration but may also prolong their effects due to the slow release of steroids from these internal stores (for a review, see Akk et al. 2009 ). Although allopregnanolone is largely considered to be an ovarian-derived neurosteroid, with fluctuations occurring over the estrous cycle and during pregnancy, elevations in allopregnanolone have also been observed following stress (Purdy et al. 1991 . Periods characterized by fluctuations in neurosteroid levels are particularly vulnerable periods for the development of affective disorders, including PMDD and postpartum depression, which may involve the inability to properly regulate GABA A Rs, the main neuronal target of neurosteroids (for a review, see ).
Modulatory effects on GABA A Rs
The GABA A R family consists of 19 subunits (α 1-6, β 1-3, γ 1-3, δ, ε, θ, π and ρ 1-3) which assemble to form a pentameric structure around a chloride and bicarbonate permeable central pore. The specific receptor subunit combination (which usually consists of two α, two β and either a γ or δ subunit; Farrar et al. 1999; Tretter et al. 1997 ) determines both the channels biophysical and pharmacological properties along with its subcellular localization. For instance, γ 2 containing receptors are predominately localized at the synapse where they mediate rapid synaptic ("phasic") inhibition (Farrant and Nusser 2005) . However, receptors containing the δ subunit are localized extrasynaptically where they bind GABA with high affinity but low efficacy to generate a persistent "tonic" form of inhibition (Farrant and Nusser 2005) . While the γ2 subunit is widely expressed (Pirker et al. 2000; Wisden et al. 1992) , expression of the δ subunit is mainly restricted to the cortex, hypothalamus, cerebellum, dentate gyrus, striatum and thalamus (Hortnagl et al. 2013; Peng et al. 2002 Peng et al. , 2004 Pirker et al. 2000; Sarkar et al. 2011; Wisden et al. 1992) , where it preferentially pairs with the α 4 subunit (except in the cerebellum where it pairs with α 6 ) (Olsen and Sieghart 2008) . Neurosteroids are potent allosteric modulators of GABA A Rs, whilst at sufficiently high concentrations they can directly activate the receptor in the absence of GABA (Majewska et al. 1986 ). Although neurosteroids are active at all major GABA A R isoforms, the addition of the δ subunit confers sensitivity to low nanomolar concentrations of neurosteroids in both recombinant expression systems and in vitro slice recordings (Houston et al. 2012; Stell et al. 2003) . Indeed, neurosteroid sensitivity is greatly reduced in mice which lack the GABA A R δ subunit (Gabrd −/− mice) (Mihalek et al. 1999; Sarkar et al. 2011; Spigelman et al. 2003; Vicini et al. 2002) . Interestingly, the neurosteroid binding site is independent of the GABA A R δ subunit. Rather, the conserved neurosteroid binding sites responsible for both allosteric potentiation and direct receptor activation of GABA A Rs are found on the interface of the α and β subunits (Hosie et al. 2006) . As GABA is a poor agonist at δ subunitcontaining receptors, the greater potency of neurosteroids at these receptors is not due to the δ subunit itself but rather to the ability of neurosteroids to increase the efficacy of GABA at these receptors which is less apparent in isoforms where GABA is already an effective agonist (Bianchi and Macdonald 2003) . At higher concentrations, neurosteroids have the capacity to potentiate GABAergic inhibition on a wider range of GABA A R subtypes, including synaptic GABA A Rs that mediate the phasic form of GABAergic inhibition (Hosie et al. 2006; Hosie et al. 2009 Neurosteroid mediated potentiation of inhibitory tonic GABA A R mediated currents will have an important influence on neuronal excitability by narrowing the spatial and temporal integration of synaptic events thus increasing the current required to reach action potential threshold (Farrant and Nusser 2005) . Due to fluctuations in neurosteroid levels under physiological conditions, the GABA A Rs, must be extremely plastic to maintain an optimal level of inhibition and, thus, neuronal excitability. Thus, in addition to their influence on the biophysical and pharmacological properties of the receptors due to allosteric potentiation and direct activation of the receptors, changes in neurosteroid concentration also influences GABA A R expression patterns (see Section 3), possibly by modulating the phosphorylation state of the receptor (Abramian et al. 2010; Kuver et al. 2012) . Both increases and decreases in allopregnanolone have been associated with changes in neuronal excitability and mood which are thought to be due in part to the actions of neurosteroids at GABA A Rs making them an attractive therapeutic target. Although it has been suggested that tolerance is less likely to occur with neurosteroid-based therapies (Reddy and Rogawski 2000; commentary by Lagrange 2006) , changes in GABA A R subunit expression resulting from neurosteroid exposure may alter GABAergic inhibition by altering neurosteroid sensitivity (commentary by Lagrange 2006) . In fact, recent studies suggest neurosteroid tolerance associated with decreased expression of the GABA A R α 4 subunit (Turkmen et al. 2011) which would have significant implications for the therapeutic potential of neurosteroids. The rest of this review will discuss the changes in GABAergic inhibition evoked by fluctuations in neurosteroid level and the relevance to our understanding and potential treatment of mood disorders.
Regulation of GABA A Rs over the estrous cycle
Changes in GABAergic inhibition over the estrous cycle were originally inferred by the cyclic changes in the binding of, and responses to benzodiazepines, neurosteroids and muscimol (Aldahan et al. 1994; Martin and Williams 1995; MolinaHernandez et al. 2001; Molina-Hernandez and TellezAlcantara 2001; Reddy and Kulkarni 1999; Taherianfard and Mosavi 2011) . It has now been shown that during and immediately following periods of elevated progesterone, protein expression of α 4 , β 1 and δ subunits are increased in the periaqueductal grey matter of rats over the estrous cycle ( Fig. 1 ) (Griffiths and Lovick 2005a,b) . Similar results have been obtained in the hippocampus, where during periods of elevated progesterone and progesterone-derived neurosteroids, there is an increase in the expression of the GABA A R δ subunit ( Fig. 1) (Maguire et al. 2005; Wu et al. 2013 ) and a decrease in the expression of the γ 2 subunit (Maguire et al. 2005) . Furthermore, increases in α 4 mRNA and protein expression have also been observed in the hippocampus following progesterone withdrawal (Smith et al. 1998) . Progesterone mediated increases in δ subunit expression were blocked by the 5-α reductase inhibitor finasteride (Maguire et al. 2005; Wu et al. 2013) but not by the progesterone receptor inhibitor RU489 (mifepristone; Maguire et al. 2005) or in progesterone receptor KO mice (Wu et al. 2013) demonstrating that neurosteroids and not progesterone itself mediate these changes. These results are also mimicked in both progesterone administration and withdrawal models (Griffiths and Lovick 2005a; Gulinello et al. 2001; Hsu and Smith 2003; Shen et al. 2005) , demonstrating that sex steroids and their metabolites modify GABAergic inhibition throughout the estrous cycle by altering the expression of specific GABA A R subunits.
Changes in GABAergic inhibition over the menstrual cycle have been attributed to the development of premenstrual syndrome (PMS) and the more severe PMDD, which has just recently been recognized as a distinct mental disorder by psychiatrists in the new Diagnositc and Statistical Manual, the DSM-5 (American Psychiatric Association 2013). The most severe symptoms are reported during the luteal phase when progesterone levels rise and then begin to fall (Lovick 2012) . Thus, the pathophysiology of PMS/PMDD is thought to involve a reduction in the levels of neurosteroids. However, although some studies demonstrate alterations in the levels of neurosteroids in PMS/PMDD (Rapkin et al. 1997 ), many studies do not (for a review, see Wihlback et al. 2006 ). These findings indicate that neurosteroid levels per se do not mediate the pathophysiology of PMS/PMDD, but rather the site of action of neurosteroids, namely, GABA A Rs, may be altered. Whilst it is not possible to directly measure changes in GABA A R expression in patients suffering from PMS/PMDD, a change in saccadic eye velocity (SEV) has been used as a proxy measure of GABA A R activity in different physiological states and following pharmacological challenges (Backstrom et al. 2013 ). PMS patients have been shown to have a slower SEV compared to controls in the luteal phase suggesting differences in the composition of GABA A Rs in the circuitry controlling saccadic eye movements. Furthermore, PMS/PMDD patients are less sensitive to benzodiazepines (Sundstrom et al. 1997a,b) consistent with the hypothesis that GABAergic inhibition is altered in PMS/ PMDD patients. PMS patients also show a reduced sensitivity to pregnanolone in the luteal phase , which may reflect altered regulation of steroidogenenic enzymes over the menstrual cycle. Administration of the SSRI fluoxetine reduces symptom severity in PMS/PMDD sufferers possibly by increasing the activity of the steroidogenic enzyme 3α-HSD and allopregnanolone production independently of the 5HT system (Griffin and Mellon 1999; Lovick 2012; Marjoribanks et al. 2013; Pinna et al. 2009 ). Increased allopregnanolone production and a more gradual drop in steroid levels in the late luteal phase may help reduce the anxiogenic effects observed following rapid steroid withdrawal (Lovick 2012) . In turn, it would be anticipated that an increased tonic conductance would also be anxiolytic. Therefore, it is perplexing that negative mood symptoms are reported during periods when allopregnanolone levels are elevated. However, one would anticipate negative mood symptoms would arise due to deficits or changes in the site of action of neurosteroids (GABA A Rs) despite elevated levels of neurosteroids. Whilst studies in animal models have suggested a role for alterations in GABA A Rs in mood disorders associated with changes in ovarian hormones it remains unclear whether GABA A Rs are actually altered in patients with PMS/PMDD.
One explanation for the anxiogenic actions of neurosteroids over the estrous cycle is that, at low concentrations, neurosteroids preferentially act at inhibitory interneuron populations, reducing their output and increasing the excitability of their target neurons (Backstrom et al. 2013; Lovick 2012; Wang 2011) . Indeed, it has been suggested that increased expression of α 4 βδ receptors in GABAergic neuronal populations in the PAG following periods of elevated progesterone results in disinhibition of the principal output neurons and increased network excitation (Brack and Lovick 2007; Griffiths and Lovick 2005a,b; Lovick 2012) . However, further increases in neurosteroid levels may dampen network excitability by acting upon the γ2-containing GABA A R populations which have a lower affinity for neurosteroids creating an inverted U-shaped relationship between steroid concentration and neuronal excitability. This mirrors symptom severity with postmenopausal women who when prescribed progesterone experienced more negative mood symptoms as the serum allopregnanolone concentrations reached levels similar to those measured in the luteal phase (Andreen et al. 2005 (Andreen et al. , 2006 Wang 2011) . However, when allopregnanolone levels were increased further, the severity of reported symptoms decreased (Andreen et al. 2006 ) with similar responses observed in the aggression levels of rodents (Miczek et al. 2003) .
Changes in the neuronal intracellular chloride concentration can switch GABAergic inhibition, and therefore neurosteroid actions, from inhibitory to excitatory which may also contribute to PMS/PMDD symptoms when allopregnanolone levels are elevated (Wang 2011) . In the adult, the low intracellular chloride concentration required for GABAergic inhibition is maintained by the potassium chloride co-transporter, KCC2, which sets the GABA reversal potential (E GABA ) equal to or below the resting membrane potential (Payne et al. 1996 (Payne et al. , 2003 . However, it is now known that KCC2 surface expression and pumping efficiency is not static but tightly regulated by changes in phosphorylation state (Kahle et al. 2010 (Kahle et al. , 2013 Lee et al. 2007 Lee et al. , 2010 Rinehart et al. 2011; Rivera et al. 2002 Rivera et al. , 2004 Fig. 1 GABA A R plasticity over the estrous cycle, puberty, and pregnancy. The diagram summarizes changes in GABA A R δ subunit expression in the hippocampus and PAG relative to changes in neurosteroid levels over the estrous cycle and throughout pregnancy and the postpartum period compared to virgin animals. This figure summarizes data obtained from (Griffiths and Lovick 2005a,b; Maguire et al. 2005 Maguire and Mody 2008; Wu et al. 2013) reversible changes in chloride concentration. Downregulation of KCC2 and elevated intracellular chloride can lead to a depolarizing shift in E GABA resulting in the excitatory actions of both GABA and neurosteroids. The excitatory actions of neurosteroids due to the potentiation of depolarizing δ-GABA A R mediated currents are seen in the corticotropinreleasing hormone (CRH) neurons of the paraventricular nucleus (PVN) (Sarkar et al. 2011) where KCC2 is downregulated following an acute stressor (Hewitt et al. 2009; Sarkar et al. 2011) . Differences in KCC2 expression within intracellular compartments adds an additional layer of complexity (for a review, see Wang 2011) with neurosteroids being shown to potentate excitatory GABAergic currents in the presynaptic terminal contributing to glutamate release (Kim et al. 2011) . Although reduced KCC2 function and expression levels can render neurosteroids excitable, changes in KCC2 expression levels over the estrous cycle have yet to be fully investigated. Interestingly estradiol, which effects mood in a dose dependent manner Wang 2011) , has been shown to potentate the activity of the sodium potassium chloride cotransporter NKCC1 (Nakamura et al. 2004 ) which, by pumping chloride into the cell, also reduces GABAergic inhibition. However, it is important to remember that sufficiently increasing the GABA A R mediated conductance, for instance, by elevating the extracellular GABA concentration (or potentially by elevating neurosteroid levels), can overcome the excitatory effects of depolarizing GABA due to shunting inhibition (Song et al. 2011) . Therefore, the potential effects of a loss of KCC2 function on neuronal excitability will likely be context-specific. Finally, during puberty neurosteroids have been shown to modulate α 4 βδ GABA A R mediated currents in a polarity dependent way by attenuating hyperpolarizing but not depolarizing responses Smith 2013) . This neurosteroid dependent reduction in inhibition may also contribute to negative mood symptoms in PMS/PMDD (see Section 4). These data demonstrate steroid hormone/ neurosteroid mediated changes in GABAergic inhibition over the estrous cycle which may contribute to the increased vulnerability to mood disorders during this period and similar deficits may occur under other conditions of altered steroid hormone levels, such as during puberty and pregnancy.
Regulation of GABA A Rs during puberty
Puberty is a period commonly associated with changes in mood, such as increased anxiety and mood swings in addition to being a vulnerable period for the generation of affective disorders (for a review, see Smith 2013) . Levels of steroid hormones fluctuate during puberty yet the effects of these hormonal changes on neuronal and network excitability during puberty is still relatively understudied. Allopregnanolone levels gradually increase before puberty then drops upon onset (Fadalti et al. 1999; Mannan and O'Shaughnessy 1988; Shen et al. 2007 ). The fall in allopregnanolone concentrations correspond to a transient increase in α 4 βδ expression in the CA1 region of the hippocampus (Shen et al. 2010; Smith et al. 2007 ) of female mice which are higher than those found in the adult (Shen et al. 2010 ) and can be mimicked by steroid withdrawal (Smith et al. 2006) . Administration of allopregnanolone during puberty has been shown to increase anxiety levels in mice ) whilst having anxiolytic effects when applied to pre-pubertal mice and adults (Bitran et al. 1999; Shen et al. 2007) . Although unexpected, the anxiogenic effects of neurosteroids at puberty coincide with a reported increase in the prevalence of anxiogenic effects of benzodiazepines during puberty in human children and adolescents (Massanari et al. 1997) . Shen et al. (2007) have shown that allopregnanolone can attenuate hyperpolarizing α 4 βδ-mediated currents in hippocampal CA1 pyramidal neurons by increasing the degree of receptor desensitization. Consequently, the increased α 4 βδ receptor desensitization in the presence of allopregnanolone reduced rather than potentiated the magnitude of the tonic conductance resulting in increased neuronal excitability ). Neurosteroids were not anxiogenic in mice lacking the GABA A R δ subunit (Gabrd −/− mice), supporting the role of δ-containing GABA A Rs in mediating the anxiety phenotypes observed during puberty ). In addition to increasing anxiety, the rise in hippocampal α 4 βδ expression during puberty and the increase in the tonic conductance have also been shown to impair learning and memory in the CA1 hippocampus of pubertal mice, an effect which could be rescued by an increase in allopregnanolone (Shen et al. 2010) . Therefore, changes in the magnitude of tonic inhibition within the hippocampus are influenced by changes in neurosteroid levels and may provide a novel therapeutic target for managing the development of affective disorders during puberty and adolescence.
Regulation of GABA A Rs during pregnancy and the postpartum period
The highest physiological concentrations of neurosteroids are observed during pregnancy. Progesterone levels increase 200-fold (Backstrom et al. 2013) and are paralleled by increases in the neurosteroids allopregnanolone and THDOC . High levels of neurosteroids have been shown to be essential for a successful pregnancy (Frye et al. 2011) and reach concentrations as high as 100 nM , which is sufficient to cause sedation in non-pregnant animals . Therefore, it has been suggested that plasticity in GABA A Rs occur during pregnancy and the postpartum period as a compensatory mechanism to offset the elevations in neurosteroid levels (for a review, see . It has been shown that cortical and hippocampal GABA A R γ2 mRNA Follesa et al. 1998 ) and protein Sanna et al. 2009 ) levels are decreased during pregnancy with no changes observed in α1, α2, α3, α4, β1, β2, β3 mRNA levels Follesa et al. 1998 ). This downregulation of GABA A Rs was neurosteroid dependent as no changes were observed in the presence of the 5-α reductase inhibitor finasteride ). Furthermore, the GABA A R δ-subunit is also downregulated during pregnancy in the dentate gyrus, hippocampal CA1, striatum and thalamus ( Fig. 1) Maguire and Mody 2008) . Interestingly, expression levels in the dentate gyrus return to normal 48 h postpartum (Fig. 1) when neurosteroid levels are restored to those observed in virgin animals, suggesting that changes in GABA A R expression may be a compensatory mechanism to maintain a steady level of inhibition throughout the pregnancy and postpartum period (Maguire and Mody 2008) . Consistent with this hypothesis, allopregnanolone exposure in slices from pregnant mice resulted in comparable levels of network excitability to slices from virgin animals ). Contrary to the findings in mice, an increase in δ-subunit expression in the dentate gyrus has been observed in rats (Sanna et al. 2009 ), suggesting that GABA A R plasticity maybe more complicated than a simple homeostatic mechanism or that species differences exist. However, further supporting compensatory regulation of GABA A Rs during pregnancy, increased expression of the neurosteroid resistant ε-subunit has been proposed to play an important role in preventing neurosteroid mediated inhibition of respiratory neurons during pregnancy when neurosteroids levels are particularly high (Hengen et al. 2012) .
Changes in neurosteroid concentrations during pregnancy and postpartum have also been shown to effect δ-subunit expression in hippocampal interneuron populations. A reduction in δ subunit expression has been observed in pavalbuminpositive interneurons in the CA3 region of the hippocampus during pregnancy which recovered to normal levels 48 h postpartum (Ferando and Mody 2013) . Recently, δ subunitmediated tonic GABAergic inhibition has been shown to regulate hippocampal interneuron populations (molecular layer and stratum radiatum interneurons) which dramatically controls principal neuron excitability (Lee and Maguire 2013) . Further, it has previously been shown that δ subunitmediated tonic GABAergic inhibition in pavalbumin positive interneurons contribute to the maintenance of γ-oscillations (Mann and Mody 2010) , which are linked to memory formation and cognitive functioning. In the absence of neurosteroids, the reduction in δ-subunit expression in acute slices from pregnant mice corresponded to an increase in γ-frequency oscillations. However, γ-frequency oscillations were normal when slices were exposed to 100 nM allopregnanolone (Ferando and Mody 2013) (Ferando and Mody 2013) , neurosteroid levels which are in the physiological range of those observed during pregnancy . This study provides further evidence showing that GABA A R homeostatic plasticity is essential for maintaining network function at normal levels during periods characterized by elevated levels of neurosteroids, such as pregnancy. As perturbed γ-oscillations are observed in numerous disorders (Uhlhaas and Singer 2010; Uhlhaas and Singer 2012) , uncoordinated changes in GABA A R δ subunit expression and steroid levels may contribute to postpartum depression and other neurological disorders, such as epilepsy and psychosis. Furthermore, changes in γ-frequency oscillations may also arise if unsynchronized changes in δ-subunit expression occur when neurosteroid levels fluctuate over shorter time scales such as during the estrous cycle or stress (Ferando and Mody 2013) . These data further support GABA A R plasticity during pregnancy; however, further research is required to fully appreciate the complexity of GABA A R plasticity during pregnancy and the consequences of failed plasticity, which may contribute to mood disorders associated with pregnancy, such as postpartum depression. Indeed, failure to properly regulate GABA A R subunit expression during pregnancy and the postpartum period has been suggested to play a role in postpartum depression (Maguire and Mody 2008) . Mice which are deficient in the GABA A R δ subunit (Gabrd −/− mice) and, therefore, unable to regulate GABA A R δ subunit expression throughout pregnancy and the postpartum period, exhibit depression-like behaviors which are restricted to the postpartum period (Maguire and Mody 2008) . These data demonstrate that the potential importance of plasticity in GABA A R subunit expression throughout pregnancy and the postpartum period and suggest that the inability to regulate GABA A Rs, particularly δ subunit-containing receptors, may contribute to the development of postpartum depression.
Conclusions
GABA A R plasticity has been observed over numerous physiological conditions characterized by changes in neurosteroid levels, including over the estrous cycle, during puberty, and throughout pregnancy and the postpartum period. These alterations in GABA A R subunit expression likely represent compensatory changes necessary to maintain and ideal level of inhibition in the face of altered neurosteroid levels, which can act on these receptors to potentiate the effects of GABA. A breakdown in the homeostatic plasticity of GABA A Rs under conditions of altered neurosteroid levels may explain the increased vulnerability to mood disorders during this time, such as the manifestation of PMS/PMDD and postpartum depression.
